Kyntra Bio (KYNB)
NASDAQ:KYNB
Want to see KYNB full AI Analyst Report?
Total Valuation
Kyntra Bio has a market cap or net worth of $28.13M. The enterprise value is -$8.90M.
Market Cap$28.13M
Enterprise Value-$8.90M
Share Statistics
Kyntra Bio has 4,048,112 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,048,112
Owned by Insiders3.38%
Owned by Institutions10.71%
Financial Efficiency
Kyntra Bio’s return on equity (ROE) is 40.99 and return on invested capital (ROIC) is -50.72%.
Return on Equity (ROE)40.99
Return on Assets (ROA)1.53
Return on Invested Capital (ROIC)-50.72%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee28.62K
Profits Per Employee815.34K
Employee Count225
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kyntra Bio is ―. Kyntra Bio’s PEG ratio is -0.00002.
PE Ratio―
PS Ratio5.51
PB Ratio7.93
Price to Fair Value7.93
Price to FCF-7.38
Price to Operating Cash Flow-1.31
PEG Ratio-0.00002
Income Statement
In the last 12 months, Kyntra Bio had revenue of 6.44M and earned 183.45M in profits. Earnings per share was 45.37.
Revenue6.44M
Gross Profit0.00
Operating Income-45.90M
Pretax Income-58.29M
Net Income183.45M
EBITDA-45.90M
Earnings Per Share (EPS)45.37
Cash Flow
In the last 12 months, operating cash flow was -21.38M and capital expenditures -22.00K, giving a free cash flow of -21.40M billion.
Operating Cash Flow-21.38M
Free Cash Flow-21.40M
Free Cash Flow per Share-5.29
Dividends & Yields
Kyntra Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.84
52-Week Price Change-15.49%
50-Day Moving Average7.03
200-Day Moving Average8.93
Relative Strength Index (RSI)47.46
Average Volume (3m)30.76K
Important Dates
Kyntra Bio upcoming earnings date is Aug 10, 2026, After Close (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Kyntra Bio as a current ratio of 3.39, with Debt / Equity ratio of 0.00%
Current Ratio3.39
Quick Ratio3.26
Debt to Market Cap0.00
Net Debt to EBITDA1.04
Interest Coverage Ratio5.24
Taxes
In the past 12 months, Kyntra Bio has paid -90.00K in taxes.
Income Tax-90.00K
Effective Tax Rate<0.01
Enterprise Valuation
Kyntra Bio EV to EBITDA ratio is 0.27, with an EV/FCF ratio of 2.57.
EV to Sales-1.92
EV to EBITDA0.27
EV to Free Cash Flow2.57
EV to Operating Cash Flow2.59
Balance Sheet
Kyntra Bio has $87.24M in cash and marketable securities with $0.00 in debt, giving a net cash position of $87.24M billion.
Cash & Marketable Securities$87.24M
Total Debt$0.00
Net Cash$87.24M
Net Cash Per Share$21.55
Tangible Book Value Per Share$1.11
Margins
Gross margin is 26.67%, with operating margin of -712.66%, and net profit margin of 2848.63%.
Gross Margin26.67%
Operating Margin-712.66%
Pretax Margin-905.19%
Net Profit Margin2848.63%
EBITDA Margin-712.66%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kyntra Bio is $43.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$43.00
Price Target Upside487.43% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-92.77%
EPS Growth Forecast―